Data as of 3:59pm ET
| -0.01 / -0.35%|
EDAP TMS SA markets Ablatherm for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. In March 2013, the company introduced a new innovative HIFU device, the Focal One dedicated to focal therapy of prostate cancer. Focal One is not FDA approved. The company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.
|Marc Oczachowski||Chief Executive Officer & Director|
|Eric Soyer||Chief Financial Officer|
|Emmanuel Blanc||Research Director & Vice President|
|Blandine Confort||Head-Investor Relations & Legal Affairs|
|Emeline Gleitz||Head-Media Relations|